BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.
Stifel Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 4:10 PM ET
Webcast Link
Piper Sandler 35th Annual Healthcare Conference
Date: Tuesday, November 28, 2023
Time: 1:00PM ET
Webcast Link
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. regulatory approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Contacts:
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 430-7576
Brett Whelan (media)
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.50 |
| Daily Change: | -0.06 -10.79 |
| Daily Volume: | 1,409,791 |
| Market Cap: | US$83.690M |
August 08, 2024 May 13, 2024 May 07, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
